A further source of variability is the clinicians taking part, a source which may not be entirely explained by the variations in ancillary and standard treatments which they employ. An early trial of a new treatment may wish to involve only those clinicians experienced in the use of the new treatment, who might be expected to 'get the best out of it.' The public health trial, however, would need to recognize that the best treatment identified in a trial will be used in general practice by a wide range of clinicians with a wide range of experience, and that any difficulties resulting from this need to be recognized at an early stage, by having an inclusive policy as regards participating clinicians.

0 0

Post a comment